Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Power List / 2017 / Masters of the Bench / Christopher J H Porter

Christopher J. H. Porter

Professor, Monash Institute of Pharmaceutical Sciences, Monash University

  • Profile

Meet Christopher J. H. Porter

Passion
“Scientifically, the realization that the interaction between drug formulations and digestive enzymes in the gut can dictate subsequent patterns of absorption, and that directing drugs to the lymphatic system can have both pharmacodynamic and pharmacokinetic consequences, has driven much of the activity in my lab over the last 15 years. Beyond that, a key determinant of the impact of my work has been my good fortune to work with a fantastic group of academic and industrial collaborators.”

Change
“I realize that this is a utopian and perhaps unrealistic aim, but I’d like to see a greater emphasis on addressing unmet medical need in a manner that is not driven by market size. If the lack of new solutions to combat antimicrobial resistance has taught us anything, it is perhaps that leaving the direction of drug discovery to what is most profitable, while understandable within current commercial models, is not always in our best interests.”

False

Advertisement

Recommended

False

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.